CatSci Expands Global Presence
The company continues to expand globally through the completion of the Goldman Sachs 10,000 Small Businesses program and the hiring of Dr. Jas Douville, the company’s new head of business development for North America.
CatSci, a United Kingdom-based process research and development contract research organization, is continuing to expand globally through the recent completion of the Goldman Sachs 10,000 Small Businesses program and the hiring of Dr. Jas Douville, the company’s new head of business development for North America.
The company created Douville’s position to help deliver affordable, small-molecule therapeutics to meet the evolving healthcare needs of the world. Douville has experience working in R&D, direct sales, and business development for the global chemistry and pharma industries. The company announced his addition in a Sept. 3, 2019 press release.
“By becoming a member of the CatSci team, I am joining a group of highly skilled, dedicated, and like-minded people that aim to understand and solve difficult chemistry challenges,” said Douville in the press release. “Our common goal is allowing our customers to accelerate the development path from the lab through the clinic and all the way to commercial production for novel small-molecule therapeutics.”
CatSci CEO Dr. Ross Burn also expanded the company’s global presence by completing the 10,000 Small Businesses program funded by Goldman Sachs in partnership with the Said Business School at Oxford University, the Aston Centre for Growth at Aston University, Leeds University Business School, and Manchester Metropolitan University Business School, according to the press release. The program accelerates the business growth of organizations, helps create jobs and economic opportunities, and helped CatSci expedite its expansion process and create 25 jobs as part of a two-year business plan.
“We are delighted that CatSci is going from strength to strength in its strategic expansion plan,” said Ross in the press release. “It is fantastic to have Jas on board as we apply the knowledge gained through the 10,000 Small Business Program to increase our international presence in North America and beyond.”
Source: CatSci
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
